Navigation Links
The Economist honors cancer immunotherapy pioneer James Allison
Date:11/7/2013

HOUSTON For basic science research that opened a completely new approach for treating cancer, The Economist has named James Allison, Ph.D., professor and chair of Immunology at The University of Texas MD Anderson Cancer Center, as its 2013 Innovations Award winner in Bioscience.

Allison identified an immune checkpoint molecule that turns off T cells white blood cells that are the attack dogs of the immune system before they can mount a successful response to tumors that they are primed to destroy.

An antibody that blocks that immune checkpoint molecule, unleashing a T cell attack, became the first drug to ever extend survival for patients with late-stage melanoma. The U.S. Food and Drug Administration approved ipilumumab (Yervoy) for treatment of metastatic melanoma in 2011.

"The approval of ipilimumab in 2011 represents the culmination of years of research by Dr Allison into tumor immunotherapy," said Tom Standage, Digital Editor at The Economist and chairman of the panel of 30 judges. "We are delighted to recognize his pioneering achievement in the fight against cancer."

The Economist is a 170-year-old weekly news publication based in London with a circulation of 4.5 million worldwide. Its Innovation Awards recognize significant contributions in eight fields: Bioscience, Computing and Telecommunications, Consumer Products, Energy and Environment, Process and Services, Social and Economic, No Boundaries and Corporate.

"I'm honored to receive this award, which recognizes the increasing importance of immune therapy in the treatment of cancer due to the efforts of many scientists, clinicians and patients willing to participate in clinical trials," Allison said.

The adaptive immune system routinely identifies, destroys and remembers infections and abnormal cells. Yet cancer cells evade or suppress immune attack, largely frustrating efforts to develop vaccines and other immune therapies against tumors.

Drug treats immune system, not specific tumor

"Immune checkpoint blockade treats the immune system, not the tumor, so we expect this approach to work across many types of cancer," Allison said. In addition to melanoma, ipilumumab has been effective in clinical trials against prostate, kidney, lung and ovarian cancers.

Allison's basic science research on T cell biology uncovered the receptor on these cells used to recognize and bind to antigens abnormalities that mark defective cells or viruses and bacteria for attack.

He also found that T cells require a second molecular signal to launch a response after they've bound to an antigen. And he identified a molecule called CTLA-4 that acts as an off switch to inhibit activated T cells from attacking.

This led to development of ipilumumab to block CTLA-4. In clinical trials against stage 4 melanoma, the drug extinguished the disease in 20 percent of patients for up to 12 years and counting.

Since arriving at MD Anderson in November 2012, Allison founded and directs an immunotherapy platform to cultivate, support and test new development of immunology-based drugs and combinations. MD Anderson's Moon Shots program, designed to accelerate the conversion of scientific discoveries into clinical advances that reduce cancer deaths, taps the expertise of the immunotherapy platform.

Allison earned his doctorate from The University of Texas at Austin in 1978, joining MD Anderson's faculty after his postdoctoral fellowship. He left MD Anderson for the University of California, Berkeley and later moved to Memorial Sloan-Kettering Cancer Center in New York.

He is a member of the National Academy of Sciences, the Institute of Medicine of the National Academies and has won many honors for biomedical research, including the first AACR-CRI Lloyd J. Old Award in Cancer Immunology at the annual meeting of the American Association for Cancer Research in April 2013.

Allison will receive his award at a ceremony in London on Dec. 3.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert

Related medicine news :

1. National survey of economists uncovers vast gender gap in policy views
2. EmploymentCrossing Site Mirrors Economists Speculation of Job Growth
3. Amyotrophic Lateral Sclerosis Association honors Dr. Robert Baloh, M.D.
4. ASH honors Bruce R. Blazar, M.D., and Carl H. June, M.D., with 2012 Ernest Beutler Lecture and Prize
5. ASH honors Margaret A. Goodell, Ph.D., with 2012 William Dameshek Prize
6. ASH honors David Ginsburg, M.D., and Richard Aster, M.D., with 2012 Henry M. Stratton Medal
7. Argentina honors Dr. Laurie H. Glimcher for enriching scientific cooperation
8. Speech-language researcher awarded top honors
9. Kentucky receives top honors in nations capital for health IT collaboration
10. Radiation Research Society honors 2 faculty
11. Bridges to Recovery Reaches Ten-Year Milestone as Premiere, Licensed Residential Behavioral Treatment Program and Honors Founding Medical Director Dr. Terry V. Eagan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... The Industrial ... March 5, 2017 by raising awareness of the profession of industrial design (ID) and ... robust content geared toward high school students and counselors; parents; and the greater public. ...
(Date:3/1/2017)... BEVERLY HILLS, CA (PRWEB) , ... March 01, 2017 , ... ... invasive cryoablation for the treatment of early stage breast cancer and where it fits ... Screens, Genes & The Choices We Make .” The event brings together leading cancer ...
(Date:3/1/2017)... (PRWEB) , ... March 01, 2017 , ... NYC based ... physical therapy, is pleased to announce the addition of Orthopaedic Surgeon Dr. ... graduated cum laude from Cornell University with a Bachelor of Science degree in biology. ...
(Date:3/1/2017)... ... 2017 , ... “Cleansing Thoughts; Glimpses from My Personal Journal”: ... His voice. “Cleansing Thoughts; Glimpses from My Personal Journal” is the creation of ... and crocheting baby items to donate to the Neonatal Intensive Care Units at ...
(Date:3/1/2017)... ... March 01, 2017 , ... “The Affair is Over Now Go Live ... upheaval of an extramarital affair. “The Affair is Over Now Go Live Your Life ... lay pastor who has dedicated her professional life to teaching and writing about marriage ...
Breaking Medicine News(10 mins):
(Date:3/1/2017)... Research and Markets has announced the addition of the ... report to their offering. ... This analysis is one of the most accurate studies ... date financial data derived from varied research sources to present unique ... the market during the next five years, including a deep dive ...
(Date:3/1/2017)... 2017  Aethlon Medical, Inc. (Nasdaq: AEMD), announced ... European Patent Number 2591359, entitled "METHODS AND COMPOSITIONS ... exosomes have emerged as a significant diagnostic and ... conditions, including cancer, infectious viruses, tuberculosis, Alzheimer,s, and ... is an important addition to Aethlon Medical,s patent ...
(Date:3/1/2017)... DUBLIN , Mar 01, 2017 Research and ... of In-Vitro Diagnostics Tests for Cancer & Infectious Diseases" report to ... Did you ... Sales & Marketing, U.S. Breast/Colon at Genomic Health, Inc.. - Beijing ... manufacturing base for the production of infectious diseases diagnostics in ...
Breaking Medicine Technology: